Form 4: Director Acquires Stock Tracking Units at TG Therapeutics

Laurence N. Charney, a Director at TG Therapeutics, Inc., acquired 8,325 Stock Tracking Units on June 11, 2026, with vesting contingent on continued service.

Summary

• Laurence N. Charney, a Director of TG Therapeutics, Inc. (TGTX), acquired 8,325 Stock Tracking Units (STUs) on June 11, 2026.
• Each STU represents a contingent right to receive either one share of common stock or a cash payment equivalent to the fair market value of one share.
• The determination of whether stock or cash is issued rests solely with the committee administering the Issuer's 2022 Incentive Plan.
• These STUs are set to vest on the first anniversary of the grant date, provided Mr. Charney remains in continuous service with the Issuer.
• The transaction was reported on June 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction for compensation purposes rather than a significant strategic event or financial performance indicator.

Positives

• Director Laurence N. Charney has acquired a significant number of Stock Tracking Units, indicating a commitment to the company's future.
• The acquisition of STUs aligns the director's interests with those of shareholders, as their value is tied to the company's stock performance or cash equivalent.
• The vesting condition of continuous service incentivizes long-term engagement and performance from the director.

Negatives

• The acquisition is in the form of Stock Tracking Units, which are contingent rights rather than direct ownership of common stock, introducing an element of uncertainty regarding the final form of compensation (stock or cash).
• The value of the STUs is subject to the discretion of a committee, adding a layer of management decision-making that could impact the ultimate benefit to the reporting person.

Risks

• The contingent nature of the Stock Tracking Units means the ultimate benefit (shares or cash) is not guaranteed and depends on committee discretion.
• The vesting of the STUs is contingent on the reporting person remaining in continuous service, implying a risk of forfeiture if service is terminated before the vesting date.
• The value of the STUs is tied to the future performance of TG Therapeutics, Inc., which is subject to inherent market and industry risks.

Future Outlook

The future outlook for the Stock Tracking Units is dependent on the company's performance and the committee's decision regarding the form of settlement (stock or cash) upon vesting, which is scheduled for the first anniversary of the grant date.

Management Comments

• The Stock Tracking Units represent a contingent right to receive either one share of the Issuer's common stock or a cash payment equal to the fair market value of one share, determined at the sole discretion of the committee of the Board of Directors.
• The STUs shall vest upon the first anniversary of the date of grant, provided the Reporting Person remains in continuous service with the Issuer through the Vesting Date.

Industry Context

StockSavvy.ai notes that the issuance of Stock Tracking Units is a common practice in the biopharmaceutical industry to incentivize key personnel and align their interests with long-term company value creation, especially in companies focused on research and development where stock performance can be volatile.

Related Party Transactions

• The acquisition of Stock Tracking Units by Director Laurence N. Charney is a related party transaction, as it involves compensation awarded by the company to a director.

Stakeholder Impact

• Shareholders: The alignment of director compensation with company performance through STUs can be viewed positively, potentially leading to better long-term value creation. However, the discretion in settlement form introduces some uncertainty.
• Employees: The use of incentive plans like this can contribute to a motivated workforce if it signals company stability and growth potential.
• Management: The committee's role in determining settlement form highlights internal governance processes.

Next Steps

• The Stock Tracking Units will vest on the first anniversary of the grant date (June 11, 2027), contingent on Mr. Charney's continued service.
• The committee of the Board of Directors will determine whether the STUs will be settled in common stock or cash.

Key Dates

Keywords

TG Therapeutics, TGTX, Form 4, Insider Trading, Stock Tracking Units, Director Compensation, Beneficial Ownership, Securities Exchange Act, Laurence N. Charney, Incentive Plan